CA2086531A1 - Compose immunoreactif - Google Patents

Compose immunoreactif

Info

Publication number
CA2086531A1
CA2086531A1 CA002086531A CA2086531A CA2086531A1 CA 2086531 A1 CA2086531 A1 CA 2086531A1 CA 002086531 A CA002086531 A CA 002086531A CA 2086531 A CA2086531 A CA 2086531A CA 2086531 A1 CA2086531 A1 CA 2086531A1
Authority
CA
Canada
Prior art keywords
igm
iga
compound according
immunoreactive compound
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002086531A
Other languages
English (en)
Inventor
Ebo S. Bos
Petrus J. Boon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo NV
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2086531A1 publication Critical patent/CA2086531A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002086531A 1990-07-03 1991-06-28 Compose immunoreactif Abandoned CA2086531A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP90201781 1990-07-03
EP90201781.3 1990-07-03
PCT/EP1991/001223 WO1992000763A1 (fr) 1990-07-03 1991-06-28 Compose immunoreactif

Publications (1)

Publication Number Publication Date
CA2086531A1 true CA2086531A1 (fr) 1992-01-04

Family

ID=8205056

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002086531A Abandoned CA2086531A1 (fr) 1990-07-03 1991-06-28 Compose immunoreactif

Country Status (7)

Country Link
EP (1) EP0537222A1 (fr)
JP (1) JPH05507924A (fr)
KR (1) KR930701201A (fr)
CA (1) CA2086531A1 (fr)
FI (1) FI925804A0 (fr)
HU (1) HUT63343A (fr)
WO (1) WO1992000763A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9824632D0 (en) * 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU556548B2 (en) * 1980-03-03 1986-11-06 Milton David Goldenberg Tumor localization and therapy with labeled antibodies and antibody fragments specific to tumor-associated markers
CA1168150A (fr) * 1981-12-18 1984-05-29 The Governors Of The University Of Alberta Conjugats d'albumine et d'agents therapeutiques
NZ210867A (en) * 1984-01-31 1989-01-06 Litton Bionetics Inc Tumour-specific monoclonal antibodies, production thereof and use
EP0293524A1 (fr) * 1987-06-02 1988-12-07 Vasocor Immunoessai de plaque athérosclérotique
EP0295719A3 (fr) * 1987-06-19 1989-12-20 The Agouron Institute Antigène SM-D, le clonant de l'antigène SM-D et la détection de lupus érythémateux systémique en utilisant cet antigène SM-D
ATE82136T1 (de) * 1987-08-10 1992-11-15 Miles Inc Gereinigtes igm.
US4937183A (en) * 1988-02-03 1990-06-26 Cytogen Corporation Method for the preparation of antibody-fragment conjugates
EP0398872A1 (fr) * 1988-02-12 1990-11-28 HighTech Receptor AB Substance de liaison d'immunoglobuline, sous-fragments, leur procede de preparation, kit de reactif et organismes de liaison d'immunoglobuline
US4983529A (en) * 1988-06-10 1991-01-08 Abbott Laboratories Immunoassay for HIV-I antigens using F(AB')2 fragments as probe
KR900005995A (ko) * 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
WO1990011091A1 (fr) * 1989-03-27 1990-10-04 Centocor, Inc. COMPOSITIONS SERVANT A STABILISER DES ANTICORPS D'IMMUNOGLOBULINE IgM

Also Published As

Publication number Publication date
HU9204170D0 (en) 1993-04-28
WO1992000763A1 (fr) 1992-01-23
JPH05507924A (ja) 1993-11-11
KR930701201A (ko) 1993-06-11
FI925804A (fi) 1992-12-21
EP0537222A1 (fr) 1993-04-21
FI925804A0 (fi) 1992-12-21
HUT63343A (en) 1993-08-30

Similar Documents

Publication Publication Date Title
AU636872B2 (en) Cross-linked antibodies and processes for their preparation
JP2942356B2 (ja) 毒素および薬剤を含む治療用複合体
US5116944A (en) Conjugates having improved characteristics for in vivo administration
US4350626A (en) Antitumor hybrid and process for the preparation thereof
AU611397B2 (en) Method of purifying toxin conjugates using hydrophobic interaction chromatography
US5747446A (en) Modified polypeptides with increased biological activity
AU659427B2 (en) Site-specific conjugation of immunoglobulins and detectable labels
JPS6221000B2 (fr)
JPS62181280A (ja) トリコテセン結合体を含む抗腫瘍剤
US5354554A (en) Crosslinked antibodies and processes for their preparation
EP0679094A1 (fr) Composes de ciblage
IE67320B1 (en) Cross-linked antibodies and processes for their preparation
CA2086531A1 (fr) Compose immunoreactif
US5714149A (en) Crosslinked antibodies and processes for their preparation
AU8063591A (en) Immunoreactive compound
JPH04266829A (ja) 免疫結合体を形成するための抗体の化学修飾
Trost et al. A New Immunoenzyme Tracer for Localization of Antibodies in Immunohistology: Peroxidase‐Labeled Protein A
EP0650735A2 (fr) Kit et méthode de préciblage
WO1996000087A2 (fr) Materiel de preciblage et nouveaux conjugues de preciblage
Trost et al. Ein neuer enzymgekoppelter Tracer für die Immunhistologie: Peroxidase-markiertes Protein A: Anwendung zum Nachweis und zur Titration antinukleärer Antikörper
JPH0428720B2 (fr)
Hainfeld Antibody-gold cluster conjugates
AU4605401A (en) Multimeric erythropoietin with increased biological activity
CA2126819A1 (fr) Trousse et methode de preciblage
JPH06157346A (ja) 選択性制癌剤

Legal Events

Date Code Title Description
FZDE Dead